Please assess the completion status of the following clinical trial:

Trial Title: Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have advanced-stage cancer and anxiety.~* Be between the ages of 18 - 70.~Note: The location for the two treatment sessions is Los Angeles, California. Treatment sessions are scheduled three to six weeks apart, and they include one overnight hospital stay both times.~Exclusion Criteria:~* Not have cancer that affects the central nervous system or brain function.~* Have no history of major psychiatric disorder.~* Have no kidney disease, abnormal liver functions, epilepsy, or cardiovascular disease, including untreated hypertension.~* Not be taking insulin, oral hypoglycemic, anti-seizure, or cardiovascular medications (except anti-hypertensive drugs).~* May take PRN benzodiazepines up to 3 days before the session.~* No Prozac for the previous 5 weeks.~* No medications the day of and the day after treatment sessions, except may take ongoing adjuvant chemotherapy as prescribed, prescribed or over-the-counter non-narcotic pain medication at any time, and narcotic pain medications up to eight hours before administration of psilocybin and six hours after administration.~* No alcohol consumption the day before, the day of, and the day after a session.~* Female subjects of childbearing potential must have a negative pregnancy test and agree to use an effective form of birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Psilocybin (Type: EXPERIMENTAL): Single, 6-hour treatment with 0.2 mg/kg active psilocybin capsule.
- Active Niacin Placebo (Type: ACTIVE_COMPARATOR): Each subject functioned as their own control, receiving niacin placebo capsule in a single 6-hour session.

Based on this trial design, predict the completion outcome and termination type (if applicable).